- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03267459
Can Pretreatment MRI be Used to Predict Intra-arterial Chemotherapy Response in Retinoblastoma? (PREDIR)
July 10, 2023 updated by: Fondation Ophtalmologique Adolphe de Rothschild
Prediction of the Response Using Dynamic Contrast-enhanced Magnetic Resonance Imaging Before Intra-arterial Chemotherapy in Children With Retinoblastoma
Retinoblastoma is the most frequent intraocular tumor in children and represents 6% of all pediatric cancers before the age of 5 years-old.
The outcome is now excellent with 95 to 97% of 5-years survival rate.
Conservative treatments are being more and more used, and intra arterial chemotherapy is one of the adjuvant treatments proposed to the children.
The treatment is efficient in most cases, but a small proportion of children will have an early progression after treatment.
MRI is used for the diagnosis of retinoblastoma.
We aim to find prognostic factors using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) for early identification of children response to intra arterial chemotherapy.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Estimated)
60
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Augustin Lecler, MD
- Email: alecler@for.paris
Study Contact Backup
- Name: Laurence Salomon, MD PhD
- Phone Number: 0148036431
- Email: lsalomon@for.paris
Study Locations
-
-
-
Paris, France, 75019
- Recruiting
- Fondation A De Rothschild
-
Contact:
- Augustin Lecler
- Email: alecler@for.paris
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
patient with retinoblastoma, undergoing intra arterial chemotherapy
Description
Inclusion Criteria:
- grade B to D retinoblastoma
- prescription of intra arterial chemotherapy
Exclusion Criteria:
- none
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
response to chemotherapy
Time Frame: 18 months
|
Persistence of ocular scarring (= favorable outcome)18 months after the end of the treatment by intra-arterial chemotherapy.
|
18 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Augustin Lecler, MD, Fondation OPH A de Rothschild
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 11, 2018
Primary Completion (Estimated)
January 1, 2025
Study Completion (Estimated)
July 1, 2026
Study Registration Dates
First Submitted
August 28, 2017
First Submitted That Met QC Criteria
August 28, 2017
First Posted (Actual)
August 30, 2017
Study Record Updates
Last Update Posted (Actual)
July 11, 2023
Last Update Submitted That Met QC Criteria
July 10, 2023
Last Verified
July 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Eye Diseases
- Retinal Diseases
- Neoplasms, Neuroepithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Eye Diseases, Hereditary
- Eye Neoplasms
- Retinal Neoplasms
- Retinoblastoma
Other Study ID Numbers
- ALR_2017_2
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Retinoblastoma
-
Children's Oncology GroupRecruitingBilateral Retinoblastoma | Childhood Intraocular Retinoblastoma | Unilateral Retinoblastoma | Group D Retinoblastoma | Stage I RetinoblastomaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedIntraocular Retinoblastoma | Recurrent Retinoblastoma | Extraocular RetinoblastomaUnited States, Canada, Puerto Rico
-
Children's Hospital Los AngelesRecruitingRetinoblastoma | Retinoblastoma Bilateral | Retinoblastoma UnilateralUnited States
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI)RecruitingCancer Survivor | Retinoblastoma | Unilateral Retinoblastoma | Intraocular Retinoblastoma | Biological SiblingUnited States, Canada
-
Memorial Sloan Kettering Cancer CenterRecruitingRetinoblastoma | Pediatric RetinoblastomaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedIntraocular RetinoblastomaUnited States, Canada, Australia, New Zealand, India
-
All India Institute of Medical Sciences, New DelhiCouncil of Scientific and Industrial Research, IndiaUnknownIntraocular RetinoblastomaIndia
-
Amsterdam UMC, location VUmcRecruitingRetinoblastoma | Trilateral RetinoblastomaNetherlands
-
Hospital JP GarrahanHospital San Juan de Dios, SantiagoActive, not recruitingUnilateral RetinoblastomaArgentina
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedUnilateral RetinoblastomaUnited States
Clinical Trials on Dynamic contrast-enhanced MRI
-
University of CincinnatiActive, not recruiting
-
University Hospital, BordeauxCompletedTransplantation, Kidney | Graft Occlusion, VascularFrance
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); National Institute of Dental and Craniofacial...Recruiting
-
Egyptian Medical SyndicateCompleted
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)RecruitingGliosarcoma | Recurrent GlioblastomaUnited States
-
Maastricht University Medical CenterCompletedCerebral Hemorrhage | Cerebral Small Vessel Disease | Blood-Brain Barrier Permeability | Cortical StrokeNetherlands
-
Memorial Sloan Kettering Cancer CenterOregon Health and Science University; DeltaPoint,Inc.Completed
-
OHSU Knight Cancer InstituteNational Cancer Institute (NCI)CompletedChildhood Brain Neoplasm | Recurrent Childhood Brain NeoplasmUnited States
-
Medical University of South CarolinaBayerRecruiting
-
Frederiksberg University HospitalOak FoundationUnknown